Chris Beyrer
Director, Duke Global Health Institute
Gary Hock Distinguished Professor in Global Health
Professor of Medicine
Research Professor of Global Health
Appointment:
Chris Beyrer
Director, Duke Global Health Institute
Gary Hock Distinguished Professor in Global Health
Professor of Medicine
Research Professor of Global Health
Chris Beyrer, MD, MPH, an internationally recognized epidemiologist who has worked on the front lines of HIV/AIDS and COVID-19 treatment and research, became director of the Duke Global Health Institute in August 2022.
Beyrer has led collaborative research on HIV epidemiology, prevention and treatment in Southeast Asia, Sub-Saharan Africa, and Eastern Europe and Central Asia for more than 30 years. He is past president of the International AIDS Society, the world’s largest body of HIV professionals, and currently serves as an advisor to the U.S. President’s Emergency Plan for AIDS Relief (PEPFAR), the HIV Vaccine Trials Network, the World Health Organization, and Physicians for Human Rights. The author of over 400 scientific papers, he was named in 2022 to the annual list of the world’s most cited scientists.
Before coming to Duke, Beyrer was the inaugural Desmond M. Tutu Professor of Public Health and Human Rights at the Johns Hopkins Bloomberg School of Public Health, where he served as associate director of the JHU Center for AIDS Research and the Center for Global Health. He was the founding director of the Center for Public Health and Human Rights. He received his medical degree from SUNY Downstate Health Sciences University and holds a Master of Public Health from Johns Hopkins Bloomberg School of Public Health. He was elected to the National Academy of Medicine in 2014 and serves on the Academy’s Board for Global Health and on the Committee for Human Rights.
Publications
-
Cooney EE, Reisner SL, Poteat TC, Althoff KN, Radix A, Stevenson M, et al. Brief Report: Interest in Long-acting Injectable PrEP among Transgender Women in Eastern and Southern United States. Journal of Acquired Immune Deficiency Syndromes. 2024 Sep 1;97(1):19–25.Chemnasiri T, Varangrat A, Wirtz AL, Decker MR, Okanurak K, Janyam S, et al. Perceived Feasibility and Acceptability of HIV Prevention Research With Daily Oral PrEP Among Young Transgender Women (YTGW) Who Sell or Trade Sex in Bangkok and Pattaya, Thailand. AIDS Educ Prev. 2024 Aug;36(4):244–60.Farley JE, Beuchamp G, Bergman A, Hughes JP, Batey DS, Del Rio C, et al. The Impact of Stigma and Sexual Identity on PrEP Awareness and Use Among At-Risk Men Who Have Sex With Men in Four U.S. Cities (HPTN 078). Stigma Health. 2024 Aug;9(3):400–10.Brown EE, Patel EU, Poteat TC, Mayer K, Wawrzyniak AJ, Radix AE, et al. Prevalence of Sexually Transmitted Infections Among Transgender Women With and Without HIV in the Eastern and Southern United States. J Infect Dis. 2024 Jun 14;229(6):1614–27.
See more publications at Scholars@Duke